Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Voyager Therapeutics Inc (Voyager) is a biotechnology company focused on developing genetic medicines for neurological diseases. Its pipeline products include VY7523, an anti-tau antibody for Alzheimer's disease; VY1706, a tau-silencing siRNA gene therapy for Alzheimer's disease; NBIB-223, an FXN gene therapy for Friedreich's ataxia; a GBA1 Gene Therapy program for Gaucher disease and Parkinson's disease; and a TDP-43 Small Molecule program for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The company utilizes its proprietary TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform to identify novel AAV capsids with enhanced blood-brain barrier penetration and CNS tropism. Voyager Therapeutics is headquartered in Lexington, Massachusetts, the US.
Headquarters
United States of America
Address
75 Hayden Avenue, Lexington, Massachusetts, 02421
Website
www.voyagertherapeutics.com
Telephone
1 857 2595340
No of Employees
141
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VYGR (NASD)
Revenue (2024)
$40.4M
-49.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-84.2%
(2024 vs 2023)
Market Cap*
$115.2M
Net Profit Margin (2024)
XYZ
-265.0%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| VY7523: Alzheimer’s Disease | TRACER |
| VY1706: Alzheimer’s Disease | |
| SOD1 Silencing Gene Therapy (siRNA) – ALS (Amyotrophic Lateral Sclerosis) | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Voyager Therapeutics Inc | Merck & Co Inc | Pfizer Inc | Biogen Inc | Sarepta Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Lexington | Rahway | New York City | Cambridge | Cambridge |
| State/Province | Massachusetts | New Jersey | New York | Massachusetts | Massachusetts |
| No. of Employees | 141 | 75,000 | 75,000 | 7,500 | 835 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Higgins | Chairman | Executive Board | 2019 | 63 |
| Alfred Sandrock, M.D., Ph.D. | Chief Executive Officer; Director | Executive Board | - | 68 |
| Jacquelyn Fahey Sandell | Chief Legal Officer | Senior Management | 2023 | 56 |
| Todd Carter, Ph.D. | Chief Scientific Officer | Senior Management | 2022 | 55 |
| Robin Swartz | President | Senior Management | 2026 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer